AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

CL

1-19 (cancelled).

20 (previously presented). A kit of parts comprising:

(a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and

(b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,

which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

21 (currently amended). ~~A~~ The kit of parts as claimed in Claim 20, wherein the prodrug of component (b) is a prodrug of the thrombin inhibitor of component (a).

22. (currently amended). ~~A~~ The kit of parts as claimed in Claim 20, wherein components (a) and (b) are suitable for sequential, separate or simultaneous use in the treatment of a condition in which inhibition of thrombin is required or desired.

23 (currently amended). ~~A~~ The kit of parts as claimed in Claim 22, wherein the

condition is deep venous thrombosis.

24 (currently amended). ~~A~~ The kit of parts as claimed in Claim 20, wherein the thrombin inhibitor is melagatran.

Cl Cont.

25 (currently amended). ~~A~~ The kit of parts as claimed in Claim 24, wherein the prodrug is of the formula

R^1O_2C-CH_2-(*R*)Cgl-Aze-Pab-OH,

wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

26 (currently amended). ~~A~~ The kit of parts as claimed in Claim 25, wherein R^1 represents methyl, ethyl or propyl.

27 (currently amended). ~~A~~ The kit of parts as claimed in Claim 25, wherein R^1 represents ethyl.

28 (currently amended). ~~A~~ The kit of parts as claimed in Claim 20, 21, 24 or 27, wherein the formulation comprising thrombin inhibitor, or derivative thereof, is a parenteral formulation and that comprising the prodrug, or derivative thereof, is an oral formulation.

29 (currently amended). A method of making ~~a~~ the kit of parts as defined in Claim 20, 21, 24 or 27, which method comprises bringing a component (a) into association with a component (b), thus rendering the two components suitable for administration in conjunction with each other.

Cl Cont.

30 (currently amended). ~~A~~ The kit of parts comprising:

(1) one of components (a) and (b) as defined in Claim 20, 21, 24 or 27;

together with

(2) instructions to use that component in conjunction with the other of the two components.

31 (previously presented). A pharmaceutical formulation including a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative thereof) and a prodrug of a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative of that prodrug), in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

32 (currently amended). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

(a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction

with

(b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,

to a patient suffering from, or susceptible to, such a condition in an effective amount and for a time and under conditions suitable for reducing the incidence of said condition.

Cl Cont.

33 (currently amended). ~~A~~ The method as claimed in Claim 32 in which ~~component~~ formulation (a) is administered prior to commencement of administration of ~~component~~ formulation (b).

34 (currently amended). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of a formulation as defined in Claim 31 to a patient suffering from, or susceptible to, such a condition in an effective amount and for a time and under conditions suitable for reducing the incidence of said condition.

35 (currently amended). ~~A~~ The method as claimed in Claim 32, wherein the condition is deep venous thrombosis.

36 (currently amended). ~~A~~ The method as claimed in Claim 35, wherein the thrombosis results from surgery.

37 (currently amended). ~~A~~ The method as claimed in Claim 36, wherein the surgery is gastrointestinal surgery or orthopedic surgery.

38 (currently amended). ~~A~~ The method as claimed in Claim 36, wherein ~~component~~ formulation (a) is administered parenterally prior to or after surgery and ~~component~~ formulation (b) is administered orally following that surgery.

C1 Cont.

39 (currently amended). ~~A~~ The method as claimed in Claim 36, wherein ~~component~~ formulation (a) is administered parenterally prior to and after surgery and ~~component~~ formulation (b) is administered orally following that surgery.

40 (currently amended). ~~A~~ The method as claimed in Claim 32, 35, 36, 37, 38 or 39, wherein the thrombin inhibitor is melagatran.

41 (currently amended). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

(a) a pharmaceutical formulation including melagatran, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction with

(b) a pharmaceutical formulation including a prodrug of formula

$R^1O_2C\text{-}CH_2\text{-}(R)Cgl\text{-}Aze\text{-}Pab\text{-}OH$,

wherein R^1 represents linear or branched $C_{1\text{-}6}$ alkyl and the OH group replaces

one of the amidino hydrogens in Pab, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,

to a patient suffering from, or susceptible to, such a condition in an effective amount and for a time and under conditions suitable for reducing the incidence of said condition.

Cl Cont.

42 (currently amended). ~~A~~ The method as claimed in Claim 41, wherein R^1 represents methyl, ethyl or propyl.

43 (currently amended). ~~A~~ The method as claimed in Claim 41, wherein R^1 represents ethyl.

44 (currently amended). ~~A~~ The method as claimed in Claim 32 wherein the prodrug of ~~component~~ formulation (b) is a prodrug of the thrombin inhibitor of ~~component~~ formulation (a).

45 (currently amended). ~~A~~ The pharmaceutical formulation as claimed in Claim 31 wherein the prodrug is a prodrug of the thrombin inhibitor.

46 (currently amended). ~~A~~ The pharmaceutical formulation as claimed in Claim 31 wherein the thrombin inhibitor is melagatran.

47 (currently amended). ~~A~~ The pharmaceutical formulation as claimed in Claim 46 wherein the prodrug is of the formula

R^1O_2C-CH_2-(*R*)Cgl-Aze-Pab-OH,

wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

Cl cont.

48 (currently amended). ~~A~~ The pharmaceutical formulation as claimed in Claim 47 wherein R^1 represents methyl, ethyl, or propyl.

49 (currently amended). ~~A~~ The pharmaceutical formulation as claimed in Claim 47 wherein R^1 represents ethyl.

50 (currently amended). ~~A~~ The method as claimed in claimed 34 wherein the prodrug is a prodrug of the thrombin inhibitor.

51 (currently amended). ~~A~~ The method as claimed in Claim 34 wherein the condition is deep venous thrombosis.

52 (currently amended). ~~A~~ The method as claimed in Claim 51 wherein the thrombosis results from surgery.

53 (currently amended). ~~A~~ The method as claimed in Claim 52 wherein the surgery is gastrointestinal surgery or orthopedic surgery.

54 (currently amended). ~~A~~ The method as claimed in Claim 34 wherein the thrombin inhibitor is melagatran.

Cl conclude

55 (currently amended). ~~A~~ The method according to Claim 34 wherein the thrombin inhibitor is melagatran, and the prodrug is of formula

R^1O_2C-CH_2-(*R*)Cgl-Aze-Pab-OH,

wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amdino hydrogens in Pab.

56 (currently amended). ~~A~~ The method as claimed in Claim 55, wherein R^1 represents methyl, ethyl or propyl.

57 (currently amended). ~~A~~ The method as claimed in Claim 55, wherein R^1 represents ethyl.